ArticleCureus2025
Conjugated Hyperbilirubinemia in a Patient With COVID-19: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) was first reported at the end of 2019 and soon evolved into a deadly pandemic of the century. It has a myriad of clinical presentations and is associated with significant mortality and morbidity. We report a case of a 49-year-old Hispanic man who presented to the emergency department with complaints of productive cough, shortness of breath, fever, and body aches for the past five days. On clinical examination, he was noted to have jaundice. Laboratory results revealed conjugated hyperbilirubinemia and elevated alkaline phosphatase. The patient tested positive for COVID-19 and appropriate treatment was initiated as per hospital protocols. All potential causes of hyperbilirubinemia were systematically excluded, including autoimmune, metabolic, hemolytic, septic, drug-induced, parasitic, and biliary etiologies. Hyperbilirubinemia improved with the treatment of COVID-19. All other causes of hyperbilirubinemia must be excluded in these individuals before attributing it to COVID-19. Further research is needed to understand the disease and to guide appropriate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.